Pericardial mesothelioma is a rare malignancy tumor in dog. Due to an aggressive tumor and low survival rates, mesothelioma is frequently diagnosed at an advanced stage. The objective of this clinical report is to highlight the characteristic of this malignancy tumor to help an early diagnosis and to improve the therapeutic outcomes of this neoplastic tumor. A 10-year-old crossbreed was referred to Kasetsart University Veterinary Teaching Hospital Kamphaengsaen for the evaluation of a history of abdominal distension, lethargy and weekness. During the physical examination, the dog was tachycardia and tachypnea. Ultrasonography imaging of spleen revealed an inhomogeneous appearance and thoracic radiograph showed cardiac enlargement. Electrocardigraphy examination revealed low voltage of QRS complex amplitude. A transthoracic echocardiogram showed a large pericardial effusion with cardiac tamponade and masses were visualized in pericardial sac. Pericardiocentesis was immediately performed to alleviate the cardiac tamponade and cytologic examination was performed to identify the characteristic of pericardial effusion fluid. Clinical symptoms of acute kidney injury were progressed from the second visit including azotemia, hyponatraemia, hyperkalemia and anuria. The dog died about 2 days after admission in the critical care unit. Histopathological examination of the pericardial fluid and pericardial mass confirmed the diagnosis of pericardial mesothelioma. Mesothelioma should be considered in the diagnosis of pericardial effusion in dog. An early stage detection of pericardial mesothelioma may significantly reduction in mortality and allow for more beneficial treatment.

Aim:The objective of this study is to investigate the improvement of heart function in dogs with chronic valvular heart disease after puppy deciduous teeth stem cells (pDSCs) administration. Materials and Methods: 20 client-owned dogs with degenerative valvular heart disease underwent multiple intravenous injections of allogeneic pDSCs. Dogs were randomly assigned to two groups: (i) Control group (n=10) with standard treatment for heart failure and (ii) group with standard treatment and multiple administrations of pDSCs (n=10). Electrocardiography, complete transthoracic echocardiography, thoracic radiography, and blood pressure were recorded before and after pDSCs injections for 15, 30 and 60 days. Results: Post pDSCs injection showed measurable improvement in left ventricular ejection fraction, American College of Veterinary Internal Medicine (ACVIM) functional class significantly improved and improved quality of life scores were observed. In the control group, there were no significant enhancements in heart function or ACVIM class. Conclusions: This finding suggests that pDSCs could be a supplement for valvular heart disease treatment.